Genmab A/S (OTCMKTS:GNMSF – Get Free Report) crossed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $296.92 and traded as low as $291.08. Genmab A/S shares last traded at $301.97, with a volume of 856 shares.
Genmab A/S Stock Performance
The business’s 50 day moving average price is $292.08 and its 200-day moving average price is $297.10.
Genmab A/S (OTCMKTS:GNMSF – Get Free Report) last posted its earnings results on Thursday, May 2nd. The company reported $2.94 earnings per share (EPS) for the quarter. Genmab A/S had a net margin of 30.74% and a return on equity of 20.80%. The company had revenue of $603.22 million during the quarter.
Genmab A/S Company Profile
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.
Featured Articles
- Five stocks we like better than Genmab A/S
- How the NYSE and NASDAQ are Different, Why That Matters to Investors
- MarketBeat Week in Review – 5/13 – 5/17
- When to Sell a Stock for Profit or Loss
- Take-Two Interactive Software Offers 2nd Chance for Investors
- About the Markup Calculator
- Deere & Company’s Q2 Report: Strong Revenue, Cautious Outlook
Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.
